Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Immunovant, Inc. (IMVT) Market Cap & Valuation Ratios

Immunovant, Inc. (IMVT) has a market cap of $5.9B, with earnings according to EquiReason's reading of its SEC filings.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

IMVTImmunovant, Inc.Follow IMVT — free
Biotechnology · Healthcare
—
Price chart with a free account
Market cap
5.9B
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
9 Nov, in 16 days

Peers

biotechnology · nearest by market cap · trailing 12 months
CompanyMkt cap, $BP/EEV/SalesEV/EBITDAFCF yieldRev. growthOp. marginROIC
IMVT5.9———-6.9%———
IOVA6.4—18.7—-4.6%+35%-93%-51%
RYTM6.1—24.7—-1.7%+54%-84%-140%
LGND6.132.320.045.62.2%+55%33%9%
MANE5.8———-1.4%——-21%
KOD5.5———-2.9%———
CGON5.5—713.7—-3.3%+1030%—-25%
COGT5.4—615.8—-5.7%——-120%
ORKA5.3———-1.9%——-28%
MIRM5.2—8.9—-4.4%+44%-135%-224%
PTCT5.1—3.418.9-0.8%-43%12%—
Median of these 1032.320.032.2-2.4%+49%-84%-39%

.

Growth vs. price

each dot a company · hover or tap for values

Immunovant, Inc. — questions

What is Immunovant, Inc.'s market cap?
$5.9B.

Every figure on this page comes from Immunovant, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.